Coherus BioSciences has launched a comprehensive website offering patients and providers support services for its biosimilars.
Coherus BioSciences has launched a comprehensive website offering patients and providers support services designed to answer questions and address needs that may arise when patients begin taking a biosimilar.
“At Coherus Biosciences, we’re committed to ensuring patient access to biologics through high-quality biosimilars,” read the website.
The services include reimbursement support, patient support programs, and provider service programs. Through the reimbursement support feature, patients will be able to verify benefits for their specific insurance coverage, address questions stemming from billing details and claims submissions, and submit or appeal prior authorization determinations.
Coherus is also seeking to reduce out-of-pocket costs for patients who are commercially insured through the Coherus COMPLETE Co-Pay Assistance Program. In addition, Coherus will also be providing its biosimilars to eligible uninsured and underinsured patients through the Patient Assistance Program. Notably, however, patients covered under Medicare or Medicaid will not be eligible to enroll in the Coherus COMPLETE Co-Pay Assistance Program.
Finally, Coherus is also providing a service specifically for providers to have a central repository for all programs and services offered through a single portal. The portal will also allow providers to contact reimbursement specialists to help secure both access and reimbursement for their patients.
“We’re developing high-value biosimilar therapies backed by robust support services so that you and your patients don’t have to choose between quality and cost,” the site states.
Coherus has launched this portal ahead of its November 2018 Biosimilar User Fee Act action date for its proposed pegfilgrastim biosimilar, CHS-1701, referencing Neulasta. While Coherus’ initial filing was met with a Complete Response Letter, in May 2018, the drug maker resubmitted its Biologics License Application to the FDA after including new data from immunogenicity studies.
The pegfilgrastim biosimilar was authorized by the European Commission just last month and will be marketed under the brand name Udenyca.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.